Evidence map›Paper›PMID 31101661›Full record

ArticleThe Journal of biological chemistry2019

A chemoprobe tracks its target.

Aseem Z Ansari

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Aseem Z AnsariDepartment of Biochemistry, University of Wisconsin, Madison, Wisconsin 53706. Electronic address: azansari@wisc.edu.

Funding

Revealing Masked Specificities of Human Nuclear ReceptorsR01GM120625 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI ANSARI, ASEEM Z · 2016 to 2019
$1.7M
Deciphering the molecular and physiological cues that guide CTD patterning by Bur1/Cdk9R01GM117362 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI ANSARI, ASEEM Z · 2016 to 2019
$1.3M
NIGMS NIH HHS R01 GM117362NIGMS NIH HHS R01 GM120625
6 · The paper itself

Abstract

Small-molecule inhibitors of histone-modifying enzymes have significant clinical utility for managing diseases such as cancer. These inhibitors are usually identified and monitored through their effects on the gain or loss of specific histone marks. In cells, multiple related enzymes can place or remove a specific mark; therefore, relying on an indirect measure of inhibitor engagement can be misleading. Mascaró

Indexed as

Enzyme InhibitorsEnzyme-Linked Immunosorbent AssayHistone DemethylasesHumansEnzyme InhibitorsHistone DemethylasesKDM1A protein, human

Identifiers

PMID31101661
PMCPMC6527164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.